Recent 8-K filings for RXST

• May 6, 2026, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01 ◈ Earnings Releases

  RxSight Reports Q1 2026 Sales of $30.9M, Net Loss Widens, Reiterates Full-Year Guidance

  Q1 2026 sales of $30.9M, down 18.5% YoY, driven by 27,472 Light Adjustable Lens units sold.

• March 19, 2026, 7:59 PM ET leadership materiality 0.35 neutral item 5.02

  RxSight discloses CFO's sign-on bonus of $169K and corrects option vesting schedule

  CFO Mark Wilterding's sign-on bonus determined at $169,348.10 and paid March 13, 2026.

• February 25, 2026, 6:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  RxSight reports Q4 revenue down 19% YoY; 2025 net loss $(38.9M); issues weak 2026 guidance

  Q4 2025 revenue $32.6M (-19% YoY); LAL revenue -1%, LDD revenue -72%.

• January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 5.02item 7.01item 9.01

  RxSight preliminary Q4 2025 revenue ~$32.6M, FY2025 revenue ~$134.5M above guidance; appoints Mark Wilterding CFO

  Q4 2025 revenue ~$32.6M; FY2025 revenue ~$134.5M vs prior guidance $125-130M.

• December 23, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  RxSight enters CFO transition agreement with Thunen; reaffirms 2025 outlook

  Shelley Thunen transitions from CFO; transition and consulting agreements executed effective Dec 23, 2025.

• December 22, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02item 7.01item 9.01

  RxSight CFO Shelley Thunen to transition; consulting agreement through Dec 2026

  CFO Shelley Thunen to depart by Jan 31, 2026 or upon appointment of successor; will serve as consultant thereafter.

• December 19, 2025, 6:59 PM ET leadership materiality 0.45 neutral item 5.02

  RxSight appoints Eric Weinberg as Chief Business Development Officer, Scott Gaines as Chief Customer Officer

  Eric Weinberg appointed Chief Business Development Officer, transitioning from Chief Commercial Officer on December 18, 2025.

• November 5, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  RxSight Q3 revenue down 14% YoY to $30.3M; net loss widens to $9.8M

  Revenue $30.3M (-14% YoY); LAL volume up 6% but LDD placements down 68%.

• August 15, 2025, 7:59 PM ET leadership materiality 0.15 neutral item 5.02

  RxSight appoints director Cohen to Compensation and Audit Committees

  Raymond W. Cohen appointed to Compensation and Audit Committees effective August 14, 2025.

• August 7, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  RxSight Q2 revenue $33.6M (-4% YoY); net loss $(11.8)M; reaffirms FY2025 guidance

  Total revenue $33.6M, down 4% from $34.9M in Q2 2024; LAL units up 13%, LDD units down 49%.

• August 4, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 9.01

  RxSight appoints former Axonics CEO Raymond Cohen to board of directors

  Raymond W. Cohen, former CEO of Axonics (sold to BSX for $3.7B), appointed to RxSight board as Class I director effective July 31, 2025.

• July 8, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  RxSight preliminary Q2 revenue $33.6M, down 4% YoY; cuts FY2025 guidance to $120-130M

  Preliminary Q2 revenue ~$33.6M, down 4% YoY and 11% sequentially; LAL volume +13% YoY, LDD sales -49% YoY.

• June 4, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  RxSight shareholders re-elect three Class I directors, approve say-on-pay and auditor

  Quorum of ~79.2% (32.18M of 40.62M shares represented) at June 3 annual meeting.

• May 7, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  RxSight Q1 revenue $37.9M (+28% YoY); LAL volume up 36%

  Q1 revenue $37.9M (+28% YoY); LAL revenue +37%, LDD revenue +8%.

• April 3, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  RxSight preliminary Q1 revenue $37.9M (+28% YoY); cuts FY2025 guidance to $160M-$175M

  Preliminary Q1 2025 revenue ~$37.9M, up 28% YoY but down 6% QoQ; LAL procedure volume 27,579 (+36% YoY).

• February 25, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  RxSight Q4 revenue $40.2M (+41% YoY), LAL volume +61%; reaffirms FY2025 guidance

  Q4 revenue $40.2M (+41% YoY); full-year revenue $139.9M (+57% YoY).

• January 13, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  RxSight reports preliminary Q4/FY2024 rev ~$40.2M/$139.9M, +41%/+57% YoY; guides 2025 rev $185-197M

  Q4 2024 revenue ~$40.2M (+41% YoY); FY2024 ~$139.9M (+57% YoY).

• November 7, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  RxSight Q3 revenue $35.3M (+59% YoY); raises FY revenue guidance to $139-140M

  Revenue $35.3M, up 59% YoY; LAL procedures 24,554 (+80%), LDD installed base 888 (+51%).

• August 5, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  RxSight Q2 revenue $34.9M, +68% YoY; raises FY2024 guidance above prior range

  Revenue $34.9M in Q2 2024, up 68% from $20.8M in Q2 2023; LAL volume +92% to 24,214 lenses.

• June 6, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

  RxSight shareholders re-elect three Class III directors, approve say-on-pay, one-year frequency, and E&Y ratification

  Three Class III directors re-elected: Julie B. Andrews, Robert J. Palmisano, Tamara R. Fountain.

• May 9, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  RxSight prices $100M public stock offering at $56/share for commercial expansion

  Offering of 1,785,714 shares at $56/share; underwriters have 30-day option for 267,857 additional shares.

• May 6, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  RxSight Q1 revenue $29.5M (+69% YoY), raises FY2024 guidance

  LAL volume up 92% to 20,218 units; LDD installed base reaches 732 (+61% YoY).

• April 23, 2024, 7:59 PM ET other material materiality 0.25 neutral item 1.01 ◈ Material Agreements ×3

  RxSight enters new lease and amends two leases for Aliso Viejo facilities with ~$10.8M future minimum payments

  New 26,825 sq ft lease at 125 Columbia: base rent $41,579/mo, term June 1, 2024–Jan 31, 2031, with two 60-month renewal options.

• February 28, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  RxSight Q4 revenue $28.6M (+78% YoY); LAL volume +98% YoY; guides FY2024 rev $128-135M

  Q4 2023 revenue $28.6M, up 78% YoY, with 77 LDDs sold and 18,071 LALs (+98% YoY).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.72 · Most common event earnings

8 positive 6 negative 10 neutral

source · RXST on sec.gov